Survodutide
An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis). It has shown promising liver-fibrosis and weight data in trials.
- Half-life
- 7.0 d
- Out of system
- ~5 weeks
- Route
- Subcutaneous
- Level
- Advanced
Long-acting — weekly dosing keeps levels steady. After the last dose, roughly 97% has cleared in ~5 weeks (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What Survodutide is used for
- Dual GLP-1 and glucagon action targets both weight loss and liver fat
- Shown meaningful MASH improvement and fibrosis benefit in trials
- Once-weekly subcutaneous dosing
How it's typically used
Trial range: titrated to roughly 6 mg subcutaneously once weekly in obesity and MASH studies, as reported in the literature.
What to watch for
- GI side effects are common, particularly during dose escalation
- Glucagon agonism can raise heart rate and affect glucose, requiring monitoring
- Investigational; not approved for any use
Common questions
- What is the half-life of Survodutide?
- Survodutide has an approximate elimination half-life of 7.0 d. Long-acting — weekly dosing keeps levels steady.
- How long does Survodutide stay in your system?
- Roughly 97% of a dose has cleared after five half-lives — about ~5 weeks for Survodutide. That is the window that matters for washouts, bloodwork and surgery.
- How is Survodutide taken?
- Survodutide is typically administered by the subcutaneous route. Trial range: titrated to roughly 6 mg subcutaneously once weekly in obesity and MASH studies, as reported in the literature.
- What are the risks of Survodutide?
- GI side effects are common, particularly during dose escalation Glucagon agonism can raise heart rate and affect glucose, requiring monitoring Investigational; not approved for any use
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Full guide
Survodutide: A Tracking Guide for a GLP-1 and Glucagon Dual Agonist
A harm-reduction look at survodutide, an investigational GLP-1/glucagon agonist with obesity and MASH data, not yet approved.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.